Quantcast

Latest Novo Nordisk Stories

2014-06-19 08:30:01

Latest delivery device advancement in the basal insulin category PLAINSBORO, N.J., June 19, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest prefilled insulin delivery device Levemir(®) FlexTouch(®) (insulin detemir [rDNA origin] injection) in the United States. This device represents an advancement in insulin delivery and is based on years of feedback from endocrinologists, certified diabetes educators, primary care...

2014-06-18 23:12:11

Global Type 1 Diabetes Market 2014-2018 a research report available at ReportsnReports.com. Dallas, Texas (PRWEB) June 18, 2014 The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key...

2014-06-18 16:27:04

The Diabetes Advocacy Alliance(TM) Urges Congress to Pass the National Diabetes Clinical Care Commission Act This Congressional Session WASHINGTON, June 18, 2014 /PRNewswire-USNewswire/ -- In light of startling new data from the Center for Disease Control and Prevention's (CDC) National Diabetes Statistics Report, 2014, which show the relentless rise of diabetes and prediabetes in America, the Diabetes Advocacy Alliance(TM) (DAA) urges Congress to pass the National Diabetes Clinical...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-06 08:25:22

Diabetes leader nominated by Plainsboro's Mayor Peter Cantu PLAINSBORO, N.J., June 6, 2014 /PRNewswire/ -- Novo Nordisk, a global health care company with more than 90 years of innovation and leadership in diabetes care, will be presented today with a 2014 New Good Neighbor Award for its new LEED Silver certified US headquarters in Plainsboro, New Jersey. The company was given this award based on a variety of factors, including economic benefit/job creation, architectural merit, and...

2014-06-04 08:29:58

MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza(®) (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue, to the Lists of Medications, effective June 2, 2014. The reimbursement of Victoza(®) by the Québec Health Insurance Board (RAMQ) will allow people living with type 2 diabetes to have access to a treatment to help better manage diabetes. Québec is the first...

2014-05-31 23:04:47

Market Size - $4.9 bn in 2013, Market Growth - CAGR of 17.6%, Market Trends – Substitution of human insulin by analogs new report by Grand View Research. View complete report with TOC - http://www.grandviewresearch.com/industry-analysis/asia-pacific-insulin-market. San Francisco, California (PRWEB) May 31, 2014 The Asia Pacific market for Insulin is expected to reach USD 15.04 billion by 2020, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes,...

2014-05-21 08:29:22

DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Vaginal atrophy is defined as a decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after menopause. Up to...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related